BIOCAD

BIOCAD is an international, vertically integrated biotechnology company covering full-cycle drug discovery and development as well as commercial-scale manufacturing of therapeutic proteins for cancer and autoimmune disorders. The company has launched drug products based on original monoclonal antibodies, netakimab (anti-IL17) and prolgolimab (anti-PD1), available in the EU and China, with a dozen more innovative molecules in pre-clinical and clinical development, alongside a continuing push to introduce high-quality mAb biosimilars to emerging markets and openness to collaborations aligned with its R&D and marketing plans.